SNDX vs. PTGX, AMPH, DYN, ENTA, VKTX, IONS, CYTK, SMMT, OGN, and BBIO
Should you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include Protagonist Therapeutics (PTGX), Amphastar Pharmaceuticals (AMPH), Dyne Therapeutics (DYN), Enanta Pharmaceuticals (ENTA), Viking Therapeutics (VKTX), Ionis Pharmaceuticals (IONS), Cytokinetics (CYTK), Summit Therapeutics (SMMT), Organon & Co. (OGN), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical preparations" industry.
Protagonist Therapeutics (NASDAQ:PTGX) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership, community ranking and dividends.
Protagonist Therapeutics has a beta of 2.12, indicating that its share price is 112% more volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500.
Syndax Pharmaceuticals' return on equity of 43.42% beat Protagonist Therapeutics' return on equity.
98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.4% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Syndax Pharmaceuticals received 108 more outperform votes than Protagonist Therapeutics when rated by MarketBeat users. Likewise, 64.85% of users gave Syndax Pharmaceuticals an outperform vote while only 59.73% of users gave Protagonist Therapeutics an outperform vote.
Protagonist Therapeutics has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Syndax Pharmaceuticals had 4 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 8 mentions for Syndax Pharmaceuticals and 4 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.74 beat Syndax Pharmaceuticals' score of 0.56 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.
Protagonist Therapeutics currently has a consensus price target of $38.00, indicating a potential upside of 8.94%. Syndax Pharmaceuticals has a consensus price target of $34.42, indicating a potential upside of 76.31%. Given Protagonist Therapeutics' higher probable upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Protagonist Therapeutics.
Summary
Protagonist Therapeutics beats Syndax Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Syndax Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syndax Pharmaceuticals Competitors List
Related Companies and Tools
